Korea/Asia, Events, IPOs, Douglas Research Advisory

Douglas Kim

Nearly 30 years of experience in the Korean/Asian equity research. Major sectors coverage include the following:
- Technology 
- Consumer 
- Special Situations/Deep Value Plays
- Tender Offers/M&As
- Holdcos/Stubs
- Asian Unicorns/Private Companies

Korea/Asia, Events, IPOs

Merger Between Classys and Ilooda Likely to Reduce Local Competition

Another Major Win for Eoflow [U.S. Federal Appeals Court Issues a Decision]

Hugel: A Solid Turnaround Story With Resumption of Botulax Sales in China

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Eoflow: Financing Requirements, Changing Shareholding Structure, and the Next Steps

Douglas Research Advisory

Equity Capital Markets

<ul>
<li>On 2 July, ABL Bio (298380 KS) announced a capital raise worth 140 billion won. </li>
<li>The capital raise involves 5.77 million new shares (10.7% of outstanding shares post capital raise) at 24,229 won per share (current price is 24,150 won).</li>
<li>The proceeds from the capital raise will be used to develop next-generation ADCs (Antibody Drug Conjugates), including bispecific antibody ADCs.</li>
</ul>


On 2 July, ABL Bio (298380 KS) announced a capital raise worth 140 billion won. 
The capital raise involves 5.77 million new shares (10.7% of outstanding shares post capital raise) at 24,229 won per share (current price is 24,150 won).
The proceeds from the capital raise will be used to develop next-generation ADCs (Antibody Drug Conjugates), including bispecific antibody ADCs.


ABLBio

ABL Bio Capital Raise of 140 Billion Won